Edition:
United Kingdom

Catalyst Pharmaceuticals Inc (CPRX.OQ)

CPRX.OQ on NASDAQ Stock Exchange Capital Market

5.31USD
18 Apr 2019
Change (% chg)

$0.05 (+0.95%)
Prev Close
$5.26
Open
$5.25
Day's High
$5.33
Day's Low
$5.11
Volume
241,916
Avg. Vol
354,736
52-wk High
$5.67
52-wk Low
$1.85

About

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $234.22
Shares Outstanding(Mil.): 84.55
Dividend: --
Yield (%): --

Financials

  CPRX.OQ Industry Sector
P/E (TTM): -- 69.30 32.55
EPS (TTM): -0.20 -- --
ROI: -42.00 8.91 13.83
ROE: -42.26 10.06 15.25

UPDATE 1-U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug

Feb 28 U.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and manufacturers to resume distributing unbranded, lower-cost versions of a drug used to treat a rare neuromuscular disorder, according to a letter provided by his office to Reuters.

28 Feb 2019

Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

21 Feb 2019

UPDATE 3-Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke

Feb 21 Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.

21 Feb 2019

Catalyst defends drug price after Bernie Sanders' rebuke

Feb 21 Catalyst Pharmaceuticals Inc, targeted by U.S. Senator Bernie Sanders for high drug prices, said on Thursday that prices of its treatment for a rare neurological disorder were "in line" with similar products in the industry.

21 Feb 2019

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

11 Feb 2019

Catalyst Pharma sees net price of drug, once free, topping $300,000

NEW YORK, Feb 11 Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts.

11 Feb 2019

U.S. FDA approves Catalyst Pharma's rare disease drug

The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

28 Nov 2018

UPDATE 1-U.S. FDA approves Catalyst Pharma's rare disease drug

Nov 28 The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

28 Nov 2018

U.S. FDA approves Catalyst Pharma's rare disease drug

Nov 28 The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease.

28 Nov 2018

Earnings vs. Estimates